Bionano Genomics Q4 revenue falls as instrument sales decline

Bionano Genomics

23/03/2026 20:19

Overview

Genome analysis provider's Q4 revenue fell 3% yr/yr as instrument sales declined

Company improved Q4 gross margin to 43% from 42% yr/yr

Operating expenses for Q4 fell 22% yr/yr

Outlook

Company sees Q1 2026 revenue between $6.5 mln and $6.7 mln

Bionano expects 2026 revenue of $30 mln to $33 mln

Result Drivers

INSTRUMENT SALES - Q4 instrument revenue decreased slightly from prior year, contributing to overall revenue decline

FLOWCELL SALES - Sold 7,554 nanochannel array flowcells in Q4 2025, down 6% from Q4 2024, impacting consumables revenue

Company press release: ID:nGNX1gWsb3

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$8 mln
Q4 Gross Margin
43%
Q4 Adjusted Operating Expenses
$9.7 mln
Q4 Operating Expenses
$11.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Bionano Genomics Inc is $5.50, about 378.3% above its March 20 closing price of $1.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)